Deep Brain Stimulation (DBS) Retrospective Outcomes Study
Launched by BOSTON SCIENTIFIC CORPORATION · Sep 7, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the outcomes of a treatment called Deep Brain Stimulation (DBS) for people with conditions like Parkinson's Disease, Essential Tremor, and Dystonia. DBS involves implanting a device in the brain that helps reduce the symptoms of these disorders. The researchers want to understand how well this treatment works in real-life situations by reviewing patient records from those who have previously received DBS.
If you or a loved one has been treated with DBS or are eligible for this treatment, you may be able to participate in the study. There are no specific exclusions, meaning anyone who fits the inclusion criteria can join. Participants won't need to do anything different beyond what they are already doing for their treatment, and the study will help gather valuable information that could improve care for others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must be previously treated with or eligible for implantation with a deep brain stimulation system
- Exclusion Criteria:
- • No Exclusion Criteria
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
San Francisco, California, United States
Boise, Idaho, United States
Pittsburgh, Pennsylvania, United States
Albany, New York, United States
Winston Salem, North Carolina, United States
Phoenix, Arizona, United States
Seattle, Washington, United States
Miami, Florida, United States
Sevilla, , Spain
Würzburg, , Germany
Roeselare, , Belgium
Köln, , Germany
Düsseldorf, , Germany
Pavia, , Italy
Lübeck, , Germany
Winston Salem, North Carolina, United States
San Francisco, California, United States
Gent, , Belgium
Jena, , Germany
Patients applied
Trial Officials
Natalie Bloom Lyons
Study Director
Boston Scientific Neuromodulation Corporation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials